Stay updated with breaking news from Fixed price offer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DJ Lepermislibre: Lepermislibre announces the success of its IPO on the Euronext Growth® market in Paris Lepermislibre Lepermislibre: Lepermislibre announces the success of its IPO on the Euronext ....
DJ Lepermislibre: Lepermislibre announces the success of its IPO on the Euronext Growth® market in Paris Lepermislibre Lepermislibre: Lepermislibre announces the success of its IPO on the Euronext ....
DJ Lepermislibre: Lepermislibre announces the success of its IPO on the Euronext Growth® market in Paris Lepermislibre Lepermislibre: Lepermislibre announces the success of its IPO on the Euronext ....
<ul>
<li>
<h5>€13.8 million raised</h5>
</li>
<li>
<h5>Market capitalisation of €44.7 million</h5>
</li>
<li>
<h5>Alumna of Euronext’s FamilyShare programme</h5>
</li>
<li>
<h5>6<span>th</span> company listed on Euronext Paris in 2022</h5>
</li>
<li>
<h5>17<span>th</span> company listed on Euronext in 2022</h5>
</li>
</ul> ....
Resounding Success of Pherecydes Pharma s IPO on the Euronext Growth Market in Paris Offer oversubscribed 4 times, with global demand totaling €28.1 million Capital increase of approximately €8 million, after full exercise of the Extension Clause Trading in the Company s shares begins on February 5, 2021 (FR0011651694 ALPHE) Regulatory News: Pherecydes Pharma (Paris:ALPHE) (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the resounding success of its initial public offering on the Euronext Growth market in Paris. Guy-Charles Fanneau de La Horie, Chairman of the Executive Board of Pherecydes Pharma, says: I am particularly sensitive to the high level of interest the financial community has shown in our IPO project, both institutional and individual investors. I would like to thank all our shareholders, longstanding and new, who h ....